Catalyst-Free and Scalable Process for Synthesis of Novel MAP4K4 Inhibitor DMX-5804 and Its Glyco-Conjugates
作者:Venkateswararao Eeda、Vibhudutta Awasthi
DOI:10.1021/acs.oprd.1c00130
日期:2021.7.16
DMX-5804 is a potent and selective mitogen-activated protein kinasekinasekinase kinase-4 (MAP4K4) inhibitor, which is currently under evaluation for the treatment of myocardial infarction. Here, we report the process development of scalable and practical synthesis of DMX-5804. Process optimization resulted in the following: (1) removal of transition metals from the process and reduced duration of
申请人:Imperial College Of Science,
Technology And Medicine
公开号:EP3694866A1
公开(公告)日:2020-08-19
[EN] MAP4K4 INHIBITORS AND METHODS OF SYNTHESIS AND USE THEREOF<br/>[FR] INHIBITEURS DE MAP4K4 ET PROCÉDÉS DE SYNTHÈSE ET D'UTILISATION ASSOCIÉS
申请人:[en]THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA
公开号:WO2022246256A1
公开(公告)日:2022-11-24
The compound DMX-5804, IUPAC name 5-(4-(2-methoxyethoxy)phenyl)-7-phenyl-3,4a,7,7a-tetrahydro-4H-pyrrolo[2,3-d]pyrimidin-4-one, is a potent and selective inhibitor of mitogen-activated protein kinase kinase kinase kinase-4 (MAP4K4). The present disclosure describes a scalable and practical synthesis process for making DMX-5804. The process (1) doesn't rely on transition metals, (2) has reduced duration of reactions, (3) is streamlined with significantly improved yields using low cost raw materials, (4) includes no microwave-assisted reactions, (5) does not require column purification, and (6) generally results in crystalized products having over a 95% purity in each step. The present disclosure also describes DMX-5804 analogs and derivatives for use in inhibiting MAP4K4, and scalable and practical processes for making such DMX-5804 analogs.